Please assess the completion status of the following clinical trial:

Trial Title: LEO 29102 Cream in the Treatment of Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of atopic dermatitis defined according to Hanifin and Rajka~* IGA assessment scored as mild (2) to moderate (3) atopic dermatitis~* Treatment lesions located on the trunk and limbs~* Treatment lesions involving 3% to 10% of the total body surface area~* Patients of either gender between 18 years and 65 years of age~Exclusion Criteria:~* Systemic treatment with immunosuppressive drugs or corticosteroids within 6 weeks prior to randomisation~* Topical treatment with immunomodulators (pimecrolimus, tacrolimus) within 2 weeks prior to randomisation~* Topical treatment with corticosteroids from WHO groups II, III or IV within 1 week prior to randomisation~* Use of topical or systemic antibiotics within 2 weeks prior to randomisation~* PUVA or UVB therapy within 4 weeks prior to randomisation~* Clinical infection (viral, fungal or bacterial) on the treatment area~* Known or suspected severe renal insufficiency or severe hepatic disorders~* Patients with history of an immunocompromised disease (e.g., lymphoma, HIV, Wiskott-Aldrich Syndrome)~* Patients with concomitant serious disease (e.g., cancer) which might affect the AD treatment in this trial~* Females who are pregnant or are breast feeding~* Females intending to temporarily or permanently stop their hormonal contraceptive regime during and up to one month post study termination visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LEO 29102 0.03 mg/g cream (Type: EXPERIMENTAL): None
- LEO 29102 0.1 mg/g cream (Type: EXPERIMENTAL): None
- LEO 29102 0.3 mg/g cream (Type: EXPERIMENTAL): None
- LEO 29102 1.0 mg/g cream (Type: EXPERIMENTAL): None
- LEO 29102 2.5 mg/g cream (Type: EXPERIMENTAL): None
- LEO 29102 cream vehicle (Type: PLACEBO_COMPARATOR): None
- Elidel® cream (pimecrolimus) 10 mg/g (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).